Tag Archives: VBP

Value-Based Assessment in the UK: The Patient View

By Leela Barham. Patients are influential in the UK when it comes to access to medicines: their individual stories are highlighted in the media and the groups that represent them are credited with major policies. For example, the Rarer Cancer Foundation (RCF) has been credited in large part with the introduction of the Cancer Drugs […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , | Leave a comment

UK: Is Value Based Assessment the New Value Based Pricing?

NICE and Value Based Assessment: An Update By Leela Barham VBA is the new VBP The initial proposals for Value Based Pricing (VBP) have evolved into something very different.  Now there is focus on Value Based Assessment (VBA), which is really focusing on adding just two factors to the usual methods of assessing new medicines: […]
Posted in Europe, Global, Guest Blog, pricing | Also tagged , , , , , | Leave a comment

UK: The PPRS is Dead, Long Live the PPRS!

By Leela Barham. Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS).  It’s worth a read in full (and you can find it here) but some highlights are set out here.
Posted in Global, Guest Blog, pricing, Regulatory | Also tagged , , , , | Leave a comment

Big Pharma Welcomes Extension to England's Cancer Drug Fund, Critics Unconvinced

The Cancer Drugs Fund: Extension to 2016 By Leela Barham The Cancer Drugs Fund (CDF) in England covers the cost of cancer treatments either when the National Institute for Health and Care Excellence (NICE) has said ‘no’, or hasn’t yet come to a view.  It started with £50 million and is now £200million a year. […]
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment

UK: NICE's Looming Value-Based Pricing Challenges

NICE role in VBP The National Institute for Health and Care Excellence (NICE) will have a vital role in the post 2014 value based pricing (VBP) world.  The Department of Health (DH) who still act as the sponsor organization for the agency, has set out in more detail just what value assessment by NICE will […]
Posted in Guest Blog, Op-Ed, pricing | Also tagged , , , , | Leave a comment
  • Categories

  • Meta